<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="toxicity. Yet the recent success of multiple selective, well-characterized covalent" exact="cancer" post="drugs has renewed interest in covalent modifiers, including fragment-sized"/>
 <result pre="more potent molecule as for example in the case of" exact="cancer" post="drug venetoclax11. The researchers highlight several possibilities, one of"/>
 <result pre="new moieties at promising sites as was done for the" exact="cancer" post="drug vemurafenib12. Some of the fragments disclosed were specifically"/>
 <result pre="16.TronAEet al.Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in" exact="multiple myeloma" post="and acute myeloid leukemiaNat. Commun.20189534110.1038/s41467-018-07551-w30559424"/>
</results>
